EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Health Care Resource Utilization With Dronedarone Versus Sotalol Following Catheter Ablation in Adults With Atrial Fibrillation

Emily P Zeitler, Dara Stein, Ron Preblick, Shaum M Kabadi, David S McKindley, Jason Rashkin, Samuel Huse, Nicole Stamas, Michael H Kim

Clinical Cardiology · 2025-01 · 48 (1)

DOI: 10.1002/clc.70064 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Cardiology, online erschienen am 15.01.2025. Verfasst von Emily P Zeitler und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA. Hauptthemen laut MEDLINE: Dronedarone, Atrial Fibrillation, Sotalol, Catheter Ablation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was funded by Sanofi..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials support dronedarone use for atrial fibrillation (AF) following catheter ablation (CA); however, comparative data on health care resource utilization (HCRU) with other antiarrhythmic drugs are lacking.

Methods

Retrospective analysis of Merative MarketScan databases (January 01, 2012−March 31, 2020) comparatively assessed HCRU in US adults with AF who received dronedarone or sotalol post‐CA. Patients with ≥ 12‐months' pre‐CA data were followed from post‐CA index treatment to disenrollment, death, or study end. Sotalol‐treated patients were propensity score‐matched (1:1) with dronedarone‐treated patients. Events/100 patient‐years (PY) were analyzed by univariate generalized‐linear model with Poisson distribution. Cumulative incidence was analyzed over 12 months by Kaplan–Meier methods. Subgroup analyses were conducted by sex and patients new to dronedarone or sotalol during 12 months pre‐CA.

Results

Dronedarone and sotalol cohorts were successfully matched ( n = 1600 each). Prevalence/100‐PY for all‐cause, cardiovascular (CV)‐related, and atrial tachyarrhythmia (ATA)/AF–related HCRU was lower in dronedarone versus sotalol cohort (all p < 0.05). Cumulative incidence for all‐cause, CV‐related, ATA/AF‐related hospitalizations, and pacemaker implantation was lower in dronedarone versus sotalol cohort (all p < 0.05). Incidence of all‐cause and CV‐related hospitalizations was lower in dronedarone versus sotalol cohorts in females ( n = 460) and males ( n = 1115) (all p < 0.05) after rematching. Incidence of ATA/AF‐related hospitalization was lower in males versus females receiving dronedarone. For patients new to dronedarone or sotalol ( n = 549), HCRU results were generally consistent with primary analyses.

Conclusion

Post‐CA dronedarone, versus sotalol, lowered CV‐related HCRU in all‐comers with AF and in sex subgroups. Findings may contribute to clinical decision making post‐CA in patients with AF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DronedaroneAtrial FibrillationSotalolCatheter AblationPatient Acceptance of Health CareHumansMaleFemaleRetrospective StudiesAnti-Arrhythmia AgentsMiddle AgedAgedUnited StatesIncidenceTreatment OutcomeFollow-Up StudiesAdult

Stichwörter der Autor:innen

antiarrhythmic drugsatrial fibrillationcatheter ablationcomparative effectivenesshealth care resource utilizationobservational cohortsex analysis (Max 7)

Substanzen

DronedaroneSotalolAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
  • Real-world Evidence, Evidera, London, UK.
  • Health Economics and Outcomes Research, Sanofi, Bridgewater, New Jersey, USA.
  • Real-world Evidence, Sanofi, Bridgewater, New Jersey, USA.
  • US Medical, Sanofi, Bridgewater, New Jersey, USA.
  • Real-world Evidence, Evidera, Cambridge, Massachusetts, USA.

Förderung

  • This study was funded by Sanofi.

Zitieren

APA

Zeitler, E. P., Stein, D., Preblick, R., Kabadi, S. M., McKindley, D. S., Rashkin, J., Huse, S., Stamas, N., & Kim, M. H. (2025). Health Care Resource Utilization With Dronedarone Versus Sotalol Following Catheter Ablation in Adults With Atrial Fibrillation. Clinical Cardiology, 48(1). https://doi.org/10.1002/clc.70064

Vancouver

Zeitler EP, Stein D, Preblick R, Kabadi SM, McKindley DS, Rashkin J, et al. Health Care Resource Utilization With Dronedarone Versus Sotalol Following Catheter Ablation in Adults With Atrial Fibrillation. Clinical Cardiology. 2025;48(1). doi:10.1002/clc.70064

BibTeX
@article{Zeitler2025,
  author = {Zeitler, Emily P and Stein, Dara and Preblick, Ron and Kabadi, Shaum M and McKindley, David S and Rashkin, Jason and Huse, Samuel and Stamas, Nicole and Kim, Michael H},
  title = {Health Care Resource Utilization With Dronedarone Versus Sotalol Following Catheter Ablation in Adults With Atrial Fibrillation},
  journal = {Clinical Cardiology},
  year = {2025},
  volume = {48},
  number = {1},
  doi = {10.1002/clc.70064}
}
Kostenlos starten →